Biologics and Biosimilars Market Report 2024 (Global Edition)

Global Biologics and Biosimilars Market Report 2024 Market Size Split by Drug Class (Monoclonal Antibody, Vaccines, Recombinant Insulin, Growth Factors, Immune Modulators, Fusion Protein, Erythoprotei...

Biologics and Biosimilars Market Report Description

We have various report editions of Biologics and Biosimilars Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Biologics and Biosimilars Market Insights Video

Competitive Landscape of the Biologics and Biosimilars Market

The competitive landscape of the Biologics and Biosimilars Market is characterized by intense competition among key players such as Amgen Inc., Pfizer Inc., and Novartis AG, among others. These companies dominate the market with their extensive portfolios of biologic drugs and biosimilar products. Strategic collaborations, mergers and acquisitions, and investments in research and development are common strategies employed to maintain market dominance and drive innovation. Regulatory approvals, product quality, and pricing strategies also play significant roles in shaping the competitive dynamics of the market.

June 2022: Aeglea BioTherapeutics reported that it was unsuccessful in obtaining a biologics license application (BLA) from the FDA. The FDA declined to file the company's biologic pegzilarginase.

(Source: https://ir.aeglea.com/press-releases/news-details/2022/Aeglea-BioTherapeutics-Receives-Refusal-to-File-Letter-from-FDA-for-Pegzilarginase-for-the-Treatment-of-Arginase-1-Deficiency/default.aspx#:~:text=(NASDAQ%3A%20AGLE)%2C%20a,regarding%20the%20company's%20Biologics%20License )

Top Companies Market Share in Biologics and Biosimilars Industry: (In no particular order of Rank)

• Amgen Inc. (United States)
• Pfizer Inc. (United States)
• Novartis AG (Switzerland)
• Roche Holding AG (Switzerland)
• Johnson & Johnson (United States)
• Merck & Co.
• Inc. (United States)
• AbbVie Inc. (United States)
• Sanofi S.A. (France)
• Biogen Inc. (United States)
• Eli Lilly and Company (United States)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Biologics and Biosimilars Market

Which Region Dominates the Biologics and Biosimilars Market in 2024?

According to Cognitive Market Research, North America dominates the Biologics and Biosimilars market due to several factors. It boasts a robust regulatory framework, advanced healthcare infrastructure, and high healthcare expenditure, facilitating the development and adoption of biologic drugs and biosimilars. Additionally, favorable reimbursement policies and strong intellectual property protection encourage investment and innovation in the region. Moreover, the presence of key market players and extensive research and development activities contribute to North America's largest market share in the Biologics and Biosimilars market.

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific region is experiencing the fastest Compound Annual Growth Rate (CAGR) in the Biologics and Biosimilars market due to several factors. These include increasing healthcare expenditure, rising prevalence of chronic diseases, and expanding access to healthcare across the region. Additionally, supportive regulatory frameworks, growing investments in research and development, and strategic partnerships contribute to the rapid growth of the Biologics and Biosimilars market in the Asia Pacific region, fostering innovation and market expansion.

 

The current report Scope analyzes Biologics and Biosimilars Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Biologics and Biosimilars

According to Cognitive Market Research, the global Biologics and Biosimilars market size was estimated at USD 521584.20 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 208633.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Biologics and Biosimilars market with a market size of USD 164611.97 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. The demand is amplified by the nation's advanced healthcare infrastructure.
• The Canada Biologics and Biosimilars market had a market share of USD 25036.04 million in 2024 and is projected to grow at a CAGR of 7.0% during the forecast period. This is due to high healthcare expenditure.
• The Mexico Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 18985.66 million in 2024.

Europe Biologics and Biosimilars

According to Cognitive Market Research, the global Biologics and Biosimilars market size was estimated at USD 521584.20 Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD 156475.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.

• The United Kingdom Biologics and Biosimilars market had a market share of USD 26287.84 million in 2024 and is projected to grow at a CAGR of 7.3% during the forecast period. In the UK, Biologics and Biosimilars sales witness an upswing due to Growing demand for affordable healthcare solutions.
• The France Biologics and Biosimilars market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 14395.72 million in 2024.
• According to Cognitive Market Research, the Germany Biologics and Biosimilars market size was valued at USD 30982.10 million in 2024 and is projected to grow at a CAGR of 6.7% during the forecast period. In Germany, Biologics and Biosimilars sales surged due to established healthcare systems that promote biosimilar adoption.
• The Italy Biologics and Biosimilars market is projected to witness growth at a CAGR of 5.9% during the forecast period, with a market size of USD 13456.87 million in 2024.
• The Russia Biologics and Biosimilars market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 24253.67 million in 2024.
• The Spain Biologics and Biosimilars market is projected to witness growth at a CAGR of 5.6% during the forecast period with a market size of USD 12830.97 million in 2024
• The Luxembourg Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.6% during the forecast period, with a market size of USD 4850.73 million in 2024.
• The Portugal Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.3% during the forecast period, with a market size of USD 3285.98 million in 2024.
• The Greece Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 1877.70 million in 2024.
• Rest of Europe's Biologics and Biosimilars market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 24253.67 million in 2024.

Asia Pacific Biologics and Biosimilars

According to Cognitive Market Research, the global Biologics and Biosimilars market size was estimated at USD 521584.20 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 119964.37 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Biologics and Biosimilars market size was valued at USD 53983.96 million in 2024 and is projected to grow at a CAGR of 9.5% during the forecast period. Biologics and Biosimilars sales surge in China due to increasing healthcare expenditure.
• The Japan Biologics and Biosimilars market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 16555.08 million in 2024.
• The India Biologics and Biosimilars market had a market share of USD 14395.72 million in 2024 and is projected to grow at a CAGR of 11.8% during the forecast period. This is due to ing prevalence of chronic diseases.
• The South Korea Biologics and Biosimilars market is projected to witness growth at a CAGR of 9.1% during the forecast period, with a market size of USD 11996.44 million in 2024.
• The Australia Biologics and Biosimilars market is projected to witness growth at a CAGR of 9.7% during the forecast period, with a market size of USD 6238.15 million in 2024.
• The South East Asia Biologics and Biosimilars market is projected to witness growth at a CAGR of 11.0% during the forecast period, with a market size of USD 8277.54 million in 2024.
• The Rest of Asia Pacific Biologics and Biosimilars market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD 8517.47 million in 2024.

South America Biologics and Biosimilars

According to Cognitive Market Research, the global Biologics and Biosimilars market size was estimated at USD 521584.20 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 26079.21 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Biologics and Biosimilars market size was valued at USD 11161.90 million in 2024 and is projected to grow at a CAGR of 8.0% during the forecast period. Biologics and Biosimilars sales flourish in Brazil due to increasing healthcare investments.
• Argentina Biologics and Biosimilars market had a market share of USD 4381.31 million in 2024 and is projected to grow at a CAGR of 8.3% during the forecast period. This is due to rising demand for affordable treatment options.
• Colombia Biologics and Biosimilars market is projected to witness growth at a CAGR of 7.2% during the forecast period with a market size of USD 2321.05 million in 2024.
• Peru Biologics and Biosimilars market is projected to witness growth at a CAGR of 7.6% during the forecast period with a market size of USD 2138.50 million in 2024.
• Chile Biologics and Biosimilars market is projected to witness growth at a CAGR of 7.7% during the forecast period with a market size of USD 1877.70 million in 2024.
• The Rest of Latin America Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 4198.75 million in 2024.

Middle East and Africa Biologics and Biosimilars

According to Cognitive Market Research, the global Biologics and Biosimilars market size was estimated at USD 521584.20 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 10431.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031.

• The GCC Countries Biologics and Biosimilars market is projected to witness growth at a CAGR of 8.5% during the forecast period with a market size of USD 4464.76 million in 2024. Biologics and Biosimilars sales flourish due to increasing healthcare investments.
• The Egypt Biologics and Biosimilars market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD 1095.33 million in 2024.
• The South Africa Biologics and Biosimilars market is projected to witness growth at a CAGR of 8.7% during the forecast period, with a market size of USD 1648.21 million in 2024. Biologics and Biosimilars sales flourish in South Africa due to rising demand for affordable treatment options.
• The Turkey Biologics and Biosimilars market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 897.12 million in 2024.
• The Nigeria Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 1095.33 million in 2024.
• The Rest of MEA Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 1230.94 million in 2024.

Biologics and Biosimilars Market Analysis

How are Segments Performing in the Global Biologics and Biosimilars Market?

Biologics and Biosimilars Market Drug Class Segment Analysis

According to Cognitive Market Research, Monoclonal Antibody stands out as the dominating category. The Monoclonal Antibody Drug Class holds the largest market share in the Biologics and Biosimilars Market due to several factors. Monoclonal antibodies offer targeted therapies for various diseases, including cancer, autoimmune disorders, and inflammatory conditions, leading to their widespread adoption. Additionally, advancements in biotechnology have enabled the development of monoclonal antibody-based biologics, driving market growth. Moreover, the expiration of patents on some monoclonal antibody drugs has spurred biosimilar development, further solidifying the dominance of this drug class in the market.

The Vaccines Drug Class is experiencing the highest Compound Annual Growth Rate (CAGR) in the Biologics and Biosimilars Market due to several factors. Increasing awareness of preventive healthcare, expanding vaccination programs globally, and rising demand for innovative vaccine therapies drive market growth. Additionally, advancements in vaccine technology, such as mRNA vaccines, and the emergence of new infectious diseases and pandemics have accelerated vaccine development efforts, further propelling the growth of the Vaccines Drug Class in the market.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Biologics and Biosimilars Industry. Request a Free Sample PDF!

Biologics and Biosimilars Market Source Segment Analysis

According to Cognitive Market Research, the dominating category is Bacterial Cells. The Bacterial Cells Source holds the largest market share in the Biologics and Biosimilars Market due to several factors. Bacterial cells serve as a common and cost-effective source for producing biologics and biosimilars, especially for proteins and enzymes. Additionally, well-established fermentation processes and scalable production capabilities contribute to the widespread use of bacterial cells in biopharmaceutical manufacturing. Moreover, advancements in genetic engineering techniques enable the modification of bacterial cells to produce complex biologic drugs, further solidifying their dominance in the market.

The Yeast Cells Source is experiencing the highest Compound Annual Growth Rate (CAGR) in the Biologics and Biosimilars Market due to several reasons. Yeast cells offer advantages such as post-translational modifications and scalability, making them attractive for producing complex biologic drugs. Additionally, advancements in yeast cell engineering and fermentation technologies enhance productivity and yield. Moreover, growing demand for yeast-derived biologics and biosimilars, particularly in therapeutic proteins and vaccines, is driving the market growth of this cell source.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Biologics and Biosimilars Application Segment Analysis

Application Segment Analysis

According to Cognitive Market Research, the dominating category is Oncology. The Oncology Application holds the largest market share in the Biologics and Biosimilars Market due to several factors. Oncology represents a significant therapeutic area where biologic drugs and biosimilars play a crucial role in treating various cancers. Biologics offer targeted therapies with fewer side effects compared to traditional treatments, driving their widespread adoption in oncology. Additionally, the growing prevalence of cancer globally and the continuous development of innovative biologic drugs for oncology applications contribute to the dominance of this segment in the market.

The Autoimmune Disease Application is experiencing the highest Compound Annual Growth Rate (CAGR) in the Biologics and Biosimilars Market due to several factors. The increasing prevalence of autoimmune diseases globally drives demand for biologic drugs and biosimilars as effective treatment options. Additionally, advancements in understanding autoimmune mechanisms and the development of targeted biologic therapies contribute to market growth. Moreover, favorable regulatory environments and growing patient awareness further accelerate the adoption of biologics and biosimilars for autoimmune disease management, fueling market expansion.

• Oncology
• Autoimmune Disease
• Infectious Diseases
• Rare Disease
• Cardiovascular Disorders
• Hematological Disorders
• Other Application

Biologics and Biosimilars Manufacturing Type Segment Analysis

Manufacturing Type Segment Analysis

According to Cognitive Market Research, the dominating category is Contract Manufacturing. The Contract Manufacturing Manufacturing Type dominates the Biologics and Biosimilars Market due to several reasons. Outsourcing biologics and biosimilars manufacturing to contract manufacturing organizations (CMOs) offers flexibility, cost-effectiveness, and access to specialized expertise and technologies. Additionally, CMOs provide scalable production capacities, enabling biopharmaceutical companies to meet market demand efficiently. Moreover, outsourcing manufacturing allows companies to focus on core competencies such as research and development, driving the widespread adoption of contract manufacturing and solidifying its dominance in the market.

The In-house Manufacturing Manufacturing Type is experiencing the highest Compound Annual Growth Rate (CAGR) in the Biologics and Biosimilars Market due to several factors. Biopharmaceutical companies are increasingly investing in in-house manufacturing capabilities to maintain control over production processes, ensure product quality, and protect intellectual property rights. Additionally, advancements in bioprocessing technologies and automation enhance in-house manufacturing efficiency and scalability. Moreover, growing demand for proprietary biologic drugs and biosimilars drives investment in in-house manufacturing, fueling market growth.

• Contract Manufacturing
• In-house Manufacturing

Biologics and Biosimilars Distribution Channel Segment Analysis

Distribution Channel Segment Analysis

According to Cognitive Market Research, the dominating category is Hospital Pharmacies. The Contract Distribution Channel dominates the Biologics and Biosimilars Market for several reasons. Biopharmaceutical companies often rely on specialized distribution partners with established networks and expertise to ensure efficient and compliant distribution of their products. Contract distribution offers flexibility, scalability, and cost-effectiveness, allowing companies to focus on core competencies such as research and development. Additionally, strategic partnerships with contract distributors enable biopharmaceutical companies to reach diverse markets globally, driving widespread adoption and solidifying the dominance of this distribution channel.

The Retail Pharmacies Distribution Channel is experiencing the highest Compound Annual Growth Rate (CAGR) in the Biologics and Biosimilars Market due to several factors. Increasing demand for convenient access to biologic drugs and biosimilars, coupled with the expansion of retail pharmacy networks globally, drives market growth. Moreover, the growing prevalence of chronic diseases necessitating long-term medication management further fuels demand for biologics through retail pharmacies. Additionally, enhanced patient education and awareness about biologic treatments contribute to the rising adoption of this distribution channel.

• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Mail Order Pharmacies

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion